PRO 140--a novel CCR5 co-receptor inhibitor.
Despite an increase in the variety of anti-retroviral agents in the market, there remains a need for novel agents to treat HIV 1 infected individuals, in order to overcome existing problems with adherence, toxicities, drug interactions and viral resistance. In this article, we will describe Pro 140, one of the recently developed class of anti-retroviral agent, the CCR5 co-receptor inhibitor. We will also describe several preclinical and clinical studies that have evaluated the efficacy, tolerability and toxicity profiles of Pro-140. We will also look at how its mechanism of action and mode of delivery may change the way patients take highly active anti-retroviral therapy. There are some promising patents discussed in this short review for the use of PRO 140 as CCR5 co-receptor Inhibitor.
Khatib
Nadia
N
Genitourinary Medicine Department, Coventry and Warwickshire Hospital, Stoney Stanton Road, Coventry CV1 4FH, UK. nadiakhatib@yahoo.co.uk
Das
Satyajit
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D023241:Antiretroviral Therapy, Highly Active; D065100:CCR5 Receptor Antagonists; D015195:Drug Design; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015483:HIV Antibodies / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D055118:Medication Adherence; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065100:CCR5 Receptor Antagonists; D015483:HIV Antibodies; D023581:HIV Fusion Inhibitors; C420063:leronlimab